<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848003</url>
  </required_header>
  <id_info>
    <org_study_id>R21AT003600-01A1</org_study_id>
    <secondary_id>IND # 13691</secondary_id>
    <nct_id>NCT00848003</nct_id>
  </id_info>
  <brief_title>Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Adults on Antibiotics</brief_title>
  <acronym>PHASE</acronym>
  <official_title>Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Adults on Antibiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We believe a readily available drink containing a high dose of probiotics has the potential
      to improve compliance through many of these mechanisms. This product also has the potential
      to positively impact the health of children and adults around the world, as yogurt will
      likely be more appealing to both children and their parents for long term consumption than
      pharmaceutical-like preparations. In addition to the benefits associated with the consumption
      of probiotics, there is an increased health benefit from consuming yogurt, a nutrient dense
      food.

      More specifically, the rationale for this Phase I study is to determine safety of our drink
      and comply with the FDA's recommendations pertaining to an IND application, we will conduct a
      phase I safety study.

      We hypothesize that BB-12 is safe in healthy adults ages 18 and over.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is to assess the safety of BB-12 yogurt when consumed by generally healthy adults who are consuming antibiotics.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In addition to safety diary, participants will keep a daily diary to track number of bowel movements, if drink was consumed, if illness resulted in change in activity, over-the-counter medicines used and other illness symptoms.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Adults on Antibiotics</condition>
  <arm_group>
    <arm_group_label>1. Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12)
Probiotic, BB-12, supplemented yogurt, 4 ounces taken orally for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Strawberry flavored yogurt</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bifidobacterium animalis subsp. lactis strain BB-12</intervention_name>
    <description>Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days</description>
    <arm_group_label>1. Active</arm_group_label>
    <other_name>BB-12 probiotic supplemented yogurt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Strawberry flavored yogurt</description>
    <arm_group_label>2. Placebo</arm_group_label>
    <other_name>Strawberry flavored yogurt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to speak and write English or Spanish

          -  Refrigerator for proper storage of drink

          -  Telephone access

          -  Enrollment must take place within 24 hours of starting antibiotics

          -  Treatment with a penicillin class antibiotic regimen for 10 days for an upper
             respiratory infection;

        The following is a list of inclusive antibiotics:

          1. Amoxicillin

          2. Augmentin (amoxicillin/clavulanate)

          3. Ancef (cefazolin)

          4. Cefadroxil

          5. Cephalexin

          6. Cephradine

          7. Duricef (cefadroxil)

          8. Keflex (cephalexin)

          9. Kefzol (cefazolin)

         10. Velosef (cephradine)

         11. Ceclor (cefaclor)

         12. Cefotan

         13. Cefoxitin

         14. Ceftin (cefuroxime)

         15. Cefzil (cefprozil)

         16. Lorabid (loracarbef)

         17. Mefoxin (Cefoxitin)

         18. Zinacef (cefuroxime)

         19. Omnicef (cefdinir)

         20. Suprax (cefixime)

         21. Dicloxacillin

         22. Pen-Vee K (penicillin)

               -  Antibiotic prescribed at least twice a day

               -  Outpatients

        Exclusion Criteria:

          -  Chronic conditions, such as diabetes or asthma, that require daily medication

          -  Allergy to strawberry

          -  Active diarrhea

          -  Allergy to penicillin class antibiotic

          -  Any other medicines used except prescribed antibiotic and anti-pyretic medicines

          -  Allergy to any of the following medications

               1. Tetracycline

               2. Erythromycin

               3. Trimethoprim

               4. Ciprofloxacin

          -  Lactose intolerance.

          -  During baseline physical exam, any of the following will be grounds for exclusion;
             systolic blood pressure&gt;140, systolic blood pressure &lt;90, diastolic &gt;90, oxygen
             saturation &lt;98%, pulse rate &gt;100, pulse rate &lt;55 and respiratory rate &gt;17. These
             include all vital signs that fall outside of the &quot;normal&quot; range, including Grade 1
             through Grade 4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Heath and Nutritional Properties of Probiotics in Food Including Powder Milk With Live Lactic Acid Bacteria: Food and Agriculture Organization of the United Nations and World Health Organization2005; 2001.</citation>
  </reference>
  <reference>
    <citation>Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001 Apr 7;357(9262):1076-9.</citation>
    <PMID>11297958</PMID>
  </reference>
  <reference>
    <citation>Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, Oh W. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2005 Jan;115(1):1-4.</citation>
    <PMID>15629973</PMID>
  </reference>
  <reference>
    <citation>Mastrandrea F, Coradduzza G, Serio G, Minardi A, Manelli M, Ardito S, Muratore L. Probiotics reduce the CD34+ hemopoietic precursor cell increased traffic in allergic subjects. Eur Ann Allergy Clin Immunol. 2004 Apr;36(4):118-22.</citation>
    <PMID>15180351</PMID>
  </reference>
  <reference>
    <citation>Rosenfeldt V, Michaelsen KF, Jakobsen M, Larsen CN, Møller PL, Pedersen P, Tvede M, Weyrehter H, Valerius NH, Paerregaard A. Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr Infect Dis J. 2002 May;21(5):411-6.</citation>
    <PMID>12150178</PMID>
  </reference>
  <reference>
    <citation>Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr. 1999 Nov;135(5):564-8.</citation>
    <PMID>10547243</PMID>
  </reference>
  <reference>
    <citation>Pelletier S, Kundrat S, Hasler CM. Effects of a functional foods nutrition education program with cardiac rehabilitation patients. J Cardiopulm Rehabil. 2003 Sep-Oct;23(5):334-40.</citation>
    <PMID>14512777</PMID>
  </reference>
  <reference>
    <citation>Pelletier S, Kundrat S, Hasler CM. Effects of an educational program on intent to consume functional foods. J Am Diet Assoc. 2002 Sep;102(9):1297-300.</citation>
    <PMID>12792631</PMID>
  </reference>
  <reference>
    <citation>Hasler CM, Bloch AS, Thomson CA, Enrione E, Manning C. Position of the American Dietetic Association: Functional foods. J Am Diet Assoc. 2004 May;104(5):814-26.</citation>
    <PMID>15127071</PMID>
  </reference>
  <reference>
    <citation>Van den Driessche M, Veereman-Wauters G. Functional foods in pediatrics. Acta Gastroenterol Belg. 2002 Jan-Mar;65(1):45-51. Review.</citation>
    <PMID>12014316</PMID>
  </reference>
  <reference>
    <citation>Research MM. The Live Active Culture Yogurt Survey. Monroe Mendelsohn Research. Available at: http://www.dannon.com/dn/dnstore/cgi-bin/ProdDetEv_Cat_240861_SubCat_240857_NavRoot_200_NavID_241709_ProdID_289256.htm. Accessed May 24, 2005.</citation>
  </reference>
  <reference>
    <citation>Tuohy KM, Rouzaud GC, Brück WM, Gibson GR. Modulation of the human gut microflora towards improved health using prebiotics--assessment of efficacy. Curr Pharm Des. 2005;11(1):75-90. Review.</citation>
    <PMID>15638753</PMID>
  </reference>
  <reference>
    <citation>Veilleux BG, Rowland I. Simulation of the rat intestinal ecosystem using a two-stage continuous culture system. J Gen Microbiol. 1981 Mar;123(1):103-15.</citation>
    <PMID>7033452</PMID>
  </reference>
  <reference>
    <citation>Clausen MR, Bonnén H, Tvede M, Mortensen PB. Colonic fermentation to short-chain fatty acids is decreased in antibiotic-associated diarrhea. Gastroenterology. 1991 Dec;101(6):1497-504.</citation>
    <PMID>1955116</PMID>
  </reference>
  <reference>
    <citation>Engelbrektson AL, Korzenik JR, Sanders ME, Clement BG, Leyer G, Klaenhammer TR, Kitts CL. Analysis of treatment effects on the microbial ecology of the human intestine. FEMS Microbiol Ecol. 2006 Aug;57(2):239-50.</citation>
    <PMID>16867142</PMID>
  </reference>
  <reference>
    <citation>Klijn A, Mercenier A, Arigoni F. Lessons from the genomes of bifidobacteria. FEMS Microbiol Rev. 2005 Aug;29(3):491-509. Review.</citation>
    <PMID>15939502</PMID>
  </reference>
  <reference>
    <citation>Langhendries JP, Detry J, Van Hees J, Lamboray JM, Darimont J, Mozin MJ, Secretin MC, Senterre J. Effect of a fermented infant formula containing viable bifidobacteria on the fecal flora composition and pH of healthy full-term infants. J Pediatr Gastroenterol Nutr. 1995 Aug;21(2):177-81.</citation>
    <PMID>7472904</PMID>
  </reference>
  <reference>
    <citation>Meile L, Ludwig W, Rueger U, et al. Bifidobacterium lactis sp. nov., a moderately oxygen tolerant species isolated from fermented milk. Syst. Appl. Microbiol. 1997(20):57-46.</citation>
  </reference>
  <reference>
    <citation>Fuller R. Probiotics in human medicine. Gut. 1991 Apr;32(4):439-42. Review.</citation>
    <PMID>1902810</PMID>
  </reference>
  <reference>
    <citation>Perdigon G, de Macias ME, Alvarez S, Oliver G, de Ruiz Holgado AA. Effect of perorally administered lactobacilli on macrophage activation in mice. Infect Immun. 1986 Aug;53(2):404-10.</citation>
    <PMID>3733223</PMID>
  </reference>
  <reference>
    <citation>Wilson KH, Perini F. Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immun. 1988 Oct;56(10):2610-4.</citation>
    <PMID>3417352</PMID>
  </reference>
  <reference>
    <citation>Pongpech P, Hentges DJ, Marsh WW, Eberle ME. Effect of streptomycin administration on association of enteric pathogens with cecal tissue of mice. Infect Immun. 1989 Jul;57(7):2092-7.</citation>
    <PMID>2659535</PMID>
  </reference>
  <reference>
    <citation>Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol. 2005 Jan;21(1):44-50. Review.</citation>
    <PMID>15687884</PMID>
  </reference>
  <reference>
    <citation>Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004 May;126(6):1620-33. Review.</citation>
    <PMID>15168372</PMID>
  </reference>
  <reference>
    <citation>Davidson JN, Hirsh DC. Bacterial competition as a means of preventing neonatal diarrhea in pigs. Infect Immun. 1976 Jun;13(6):1773-4.</citation>
    <PMID>786883</PMID>
  </reference>
  <reference>
    <citation>Cong Y, Konrad A, Iqbal N, Elson CO. Probiotics and immune regulation of inflammatory bowel diseases. Curr Drug Targets Inflamm Allergy. 2003 Jun;2(2):145-54. Review.</citation>
    <PMID>14561167</PMID>
  </reference>
  <reference>
    <citation>Rautava S, Kalliomäki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol. 2002 Jan;109(1):119-21.</citation>
    <PMID>11799376</PMID>
  </reference>
  <reference>
    <citation>Isolauri E, Arvola T, Sütas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. Clin Exp Allergy. 2000 Nov;30(11):1604-10.</citation>
    <PMID>11069570</PMID>
  </reference>
  <reference>
    <citation>Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKaigney C, De Simone C, Madsen K. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology. 2004 May;126(5):1358-73.</citation>
    <PMID>15131797</PMID>
  </reference>
  <reference>
    <citation>Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004 Nov;53(11):1617-23.</citation>
    <PMID>15479682</PMID>
  </reference>
  <reference>
    <citation>Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997 Oct;11(5):853-8.</citation>
    <PMID>9354192</PMID>
  </reference>
  <reference>
    <citation>Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003 May;124(5):1202-9.</citation>
    <PMID>12730861</PMID>
  </reference>
  <reference>
    <citation>Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000 Aug;119(2):305-9.</citation>
    <PMID>10930365</PMID>
  </reference>
  <reference>
    <citation>Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999 Aug 21;354(9179):635-9.</citation>
    <PMID>10466665</PMID>
  </reference>
  <reference>
    <citation>Fukushima Y, Kawata Y, Hara H, Terada A, Mitsuoka T. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int J Food Microbiol. 1998 Jun 30;42(1-2):39-44.</citation>
    <PMID>9706796</PMID>
  </reference>
  <reference>
    <citation>Fukushima Y, Kwata Y, H H. Effect of a probiotic formula containing bifidobacteria (Nan BF) on fecal flora and fecal metaboiltes in healthy children. Bioscience Microflora. 1997(16):65-72.</citation>
  </reference>
  <reference>
    <citation>Malinen E, Mättö J, Salmitie M, Alander M, Saarela M, Palva A. PCR-ELISA II: Analysis of Bifidobacterium populations in human faecal samples from a consumption trial with Bifidobacterium lactis Bb-12 and a galacto-oligosaccharide preparation. Syst Appl Microbiol. 2002 Aug;25(2):249-58. Erratum in: Syst Appl Microbiol. 2003 Mar;26(1):154-5.</citation>
    <PMID>12353880</PMID>
  </reference>
  <reference>
    <citation>Ouwehand AC, Kurvinen T, Rissanen P. Use of a probiotic Bifidobacterium in a dry food matrix, an in vivo study. Int J Food Microbiol. 2004 Aug 15;95(1):103-6.</citation>
    <PMID>15240080</PMID>
  </reference>
  <reference>
    <citation>Bartosch S, Woodmansey EJ, Paterson JC, McMurdo ME, Macfarlane GT. Microbiological effects of consuming a synbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis, and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria. Clin Infect Dis. 2005 Jan 1;40(1):28-37. Epub 2004 Dec 6.</citation>
    <PMID>15614689</PMID>
  </reference>
  <reference>
    <citation>Salminen S, von Wright A, Morelli L, Marteau P, Brassart D, de Vos WM, Fondén R, Saxelin M, Collins K, Mogensen G, Birkeland SE, Mattila-Sandholm T. Demonstration of safety of probiotics -- a review. Int J Food Microbiol. 1998 Oct 20;44(1-2):93-106. Review.</citation>
    <PMID>9849787</PMID>
  </reference>
  <reference>
    <citation>Turck D, Bernet JP, Marx J, Kempf H, Giard P, Walbaum O, Lacombe A, Rembert F, Toursel F, Bernasconi P, Gottrand F, McFarland LV, Bloch K. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr. 2003 Jul;37(1):22-6.</citation>
    <PMID>12827001</PMID>
  </reference>
  <reference>
    <citation>Mitchell DK, Van R, Mason EH, Norris DM, Pickering LK. Prospective study of toxigenic Clostridium difficile in children given amoxicillin/clavulanate for otitis media. Pediatr Infect Dis J. 1996 Jun;15(6):514-9.</citation>
    <PMID>8783348</PMID>
  </reference>
  <reference>
    <citation>McCarty JM, Phillips A, Wiisanen R. Comparative safety and efficacy of clarithromycin and amoxicillin/clavulanate in the treatment of acute otitis media in children. Pediatr Infect Dis J. 1993 Dec;12(12 Suppl 3):S122-7.</citation>
    <PMID>8295813</PMID>
  </reference>
  <reference>
    <citation>Elstner CL, Lindsay AN, Book LS, Matsen JM. Lack of relationship of Clostridium difficile to antibiotic-associated diarrhea in children. Pediatr Infect Dis. 1983 Sep-Oct;2(5):364-6.</citation>
    <PMID>6634465</PMID>
  </reference>
  <reference>
    <citation>McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 1998 Sep-Oct;16(5):292-307. Review.</citation>
    <PMID>9892789</PMID>
  </reference>
  <reference>
    <citation>Beaugerie L, Flahault A, Barbut F, Atlan P, Lalande V, Cousin P, Cadilhac M, Petit JC; Study Group. Antibiotic-associated diarrhoea and Clostridium difficile in the community. Aliment Pharmacol Ther. 2003 Apr 1;17(7):905-12.</citation>
    <PMID>12656693</PMID>
  </reference>
  <reference>
    <citation>Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol. 2004 Mar;42(3):1203-6.</citation>
    <PMID>15004076</PMID>
  </reference>
  <reference>
    <citation>Finkelstein JA, Davis RL, Dowell SF, Metlay JP, Soumerai SB, Rifas-Shiman SL, Higham M, Miller Z, Miroshnik I, Pedan A, Platt R. Reducing antibiotic use in children: a randomized trial in 12 practices. Pediatrics. 2001 Jul;108(1):1-7.</citation>
    <PMID>11433046</PMID>
  </reference>
  <reference>
    <citation>Finkelstein JA, Metlay JP, Davis RL, Rifas-Shiman SL, Dowell SF, Platt R. Antimicrobial use in defined populations of infants and young children. Arch Pediatr Adolesc Med. 2000 Apr;154(4):395-400.</citation>
    <PMID>10768680</PMID>
  </reference>
  <reference>
    <citation>Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA. 1998 Mar 18;279(11):875-7. Erratum in: JAMA 1998 Jun 3;279(21):1702.</citation>
    <PMID>9516004</PMID>
  </reference>
  <reference>
    <citation>McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA. 1995 Jan 18;273(3):214-9. Erratum in: JAMA 1998 Feb 11;279(6):434.</citation>
    <PMID>7807660</PMID>
  </reference>
  <reference>
    <citation>McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis. 2003 Apr;9(4):432-7. Erratum in: Emerg Infect Dis. 2003 May;9(5):609.</citation>
    <PMID>12702222</PMID>
  </reference>
  <reference>
    <citation>Stille CJ, Andrade SE, Huang SS, Nordin J, Raebel MA, Go AS, Chan KA, Finkelstein JA. Increased use of second-generation macrolide antibiotics for children in nine health plans in the United States. Pediatrics. 2004 Nov;114(5):1206-11.</citation>
    <PMID>15520097</PMID>
  </reference>
  <reference>
    <citation>Cremonini F, Di Caro S, Nista EC, Bartolozzi F, Capelli G, Gasbarrini G, Gasbarrini A. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2002 Aug;16(8):1461-7. Review.</citation>
    <PMID>12182746</PMID>
  </reference>
  <reference>
    <citation>Szajewska H, Mrukowicz JZ. Use of probiotics in children with acute diarrhea. Paediatr Drugs. 2005;7(2):111-22. Review.</citation>
    <PMID>15871631</PMID>
  </reference>
  <reference>
    <citation>Szajewska H, Mrukowicz JZ. Probiotics in prevention of antibiotic-associated diarrhea: meta-analysis. J Pediatr. 2003 Jan;142(1):85.</citation>
    <PMID>12569905</PMID>
  </reference>
  <reference>
    <citation>McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006 Apr;101(4):812-22.</citation>
    <PMID>16635227</PMID>
  </reference>
  <reference>
    <citation>Hawrelak JA, Whitten DL, Myers SP. Is Lactobacillus rhamnosus GG effective in preventing the onset of antibiotic-associated diarrhoea: a systematic review. Digestion. 2005;72(1):51-6. Epub 2005 Aug 18. Review.</citation>
    <PMID>16113542</PMID>
  </reference>
  <reference>
    <citation>D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ. 2002 Jun 8;324(7350):1361. Review.</citation>
    <PMID>12052801</PMID>
  </reference>
  <reference>
    <citation>Corrêa NB, Péret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol. 2005 May-Jun;39(5):385-9.</citation>
    <PMID>15815206</PMID>
  </reference>
  <reference>
    <citation>Arvola T, Laiho K, Torkkeli S, Mykkänen H, Salminen S, Maunula L, Isolauri E. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics. 1999 Nov;104(5):e64.</citation>
    <PMID>10545590</PMID>
  </reference>
  <reference>
    <citation>Kim YI. Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr. 2004 Nov;80(5):1123-8. Review.</citation>
    <PMID>15531657</PMID>
  </reference>
  <reference>
    <citation>Williams LJ, Rasmussen SA, Flores A, Kirby RS, Edmonds LD. Decline in the prevalence of spina bifida and anencephaly by race/ethnicity: 1995-2002. Pediatrics. 2005 Sep;116(3):580-6.</citation>
    <PMID>16140696</PMID>
  </reference>
  <reference>
    <citation>Hasler CM. Functional foods: benefits, concerns and challenges-a position paper from the american council on science and health. J Nutr. 2002 Dec;132(12):3772-81.</citation>
    <PMID>12468622</PMID>
  </reference>
  <reference>
    <citation>Avery JK. Making the most of cholesterol-lowering margarines. Cleve Clin J Med. 2001 Mar;68(3):194-6.</citation>
    <PMID>11263847</PMID>
  </reference>
  <reference>
    <citation>Tammi A, Rönnemaa T, Gylling H, Rask-Nissilä L, Viikari J, Tuominen J, Pulkki K, Simell O. Plant stanol ester margarine lowers serum total and low-density lipoprotein cholesterol concentrations of healthy children: the STRIP project. Special Turku Coronary Risk Factors Intervention Project. J Pediatr. 2000 Apr;136(4):503-10.</citation>
    <PMID>10753249</PMID>
  </reference>
  <reference>
    <citation>Hasler CM. Functional Foods: Their Role in Diease Prevention and Health Promotion. Food Technology. 1998;52(2):57-62.</citation>
  </reference>
  <reference>
    <citation>Hasler CM, Kundrat S, Wool D. Functional foods and cardiovascular disease. Curr Atheroscler Rep. 2000 Nov;2(6):467-75. Review.</citation>
    <PMID>11122780</PMID>
  </reference>
  <reference>
    <citation>St-Onge MP. Dietary fats, teas, dairy, and nuts: potential functional foods for weight control? Am J Clin Nutr. 2005 Jan;81(1):7-15. Review.</citation>
    <PMID>15640454</PMID>
  </reference>
  <reference>
    <citation>Floch MH, Hong-Curtiss J. Probiotics and Functional Foods in Gastrointestinal Disorders. Curr Treat Options Gastroenterol. 2002 Aug;5(4):311-321.</citation>
    <PMID>12095479</PMID>
  </reference>
  <reference>
    <citation>Hamilton-Miller JM, Shah S, Winkler JT. Public health issues arising from microbiological and labelling quality of foods and supplements containing probiotic microorganisms. Public Health Nutr. 1999 Jun;2(2):223-9.</citation>
    <PMID>10447251</PMID>
  </reference>
  <reference>
    <citation>Beniwal RS, Arena VC, Thomas L, Narla S, Imperiale TF, Chaudhry RA, Ahmad UA. A randomized trial of yogurt for prevention of antibiotic-associated diarrhea. Dig Dis Sci. 2003 Oct;48(10):2077-82.</citation>
    <PMID>14627358</PMID>
  </reference>
  <reference>
    <citation>Alm L, Ryd-Kjellen E, Setterberg G, Blomquist L. Effect of a new fermented milk product</citation>
  </reference>
  <reference>
    <citation>Black FT, Anderson PL, Orskov J, Orskov F, Gaarslev K, Laulund S. Prophylactic efficacy of lactobacilli on traveler's diarrhea. Travel Medicine. 1989:333-335.</citation>
  </reference>
  <reference>
    <citation>Chouraqui JP, Van Egroo LD, Fichot MC. Acidified milk formula supplemented with bifidobacterium lactis: impact on infant diarrhea in residential care settings. J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):288-92.</citation>
    <PMID>15076628</PMID>
  </reference>
  <reference>
    <citation>Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet. 1994 Oct 15;344(8929):1046-9.</citation>
    <PMID>7934445</PMID>
  </reference>
  <reference>
    <citation>Phuapradit P, Varavithya W, Vathanophas K, Sangchai R, Podhipak A, Suthutvoravut U, Nopchinda S, Chantraruksa V, Haschke F. Reduction of rotavirus infection in children receiving bifidobacteria-supplemented formula. J Med Assoc Thai. 1999 Nov;82 Suppl 1:S43-8.</citation>
    <PMID>10730517</PMID>
  </reference>
  <reference>
    <citation>Schiffrin EJ, Rochat F, Link-Amster H, Aeschlimann JM, Donnet-Hughes A. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci. 1995 Mar;78(3):491-7.</citation>
    <PMID>7782506</PMID>
  </reference>
  <reference>
    <citation>Link-Amster H, Rochat F, Saudan KY, Mignot O, Aeschlimann JM. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol Med Microbiol. 1994 Nov;10(1):55-63. Erratum in: FEMS Immunol Med Microbiol 1995 Sep;12(1):83. FEMS Immunol Med Microbiol 1995 Dec;12(3-4):273.</citation>
    <PMID>7874079</PMID>
  </reference>
  <reference>
    <citation>Kankaanpaa P, Sutas Y, Salminen S, Isolauri E. Results on clinical demonstration of probiotics on children. Paper presented at: Presented at Functional Food Research in Europe, Third Workshop, 1998; Probdemo, Finland, October 1-2.</citation>
  </reference>
  <reference>
    <citation>Amrouche T, Boutin Y, Fliss I. Effects of bifidobacterial cytoplasm peptide and protein fractions on mouse lymphocyte proliferation and cytokine production. Food and Agricultural Immunology. MAR 2006;17(1):29-42.</citation>
  </reference>
  <reference>
    <citation>Amrouche T, Boutin Y, Prioult G, Fliss I. Effects of bifidobacterial cytoplasm, cell wall and exopolysaccharide on mouse lymphocyte proliferation and cytokine production. International Dairy Journal. JAN 2006;16(1):70-80.</citation>
  </reference>
  <reference>
    <citation>Matsumoto M, Ohishi H, Benno Y. Impact of LKM512 yogurt on improvement of intestinal environment of the elderly. FEMS Immunol Med Microbiol. 2001 Oct;31(3):181-6.</citation>
    <PMID>11720813</PMID>
  </reference>
  <reference>
    <citation>Obradovic D, Curic M, Ivanovic M, Trbojevic B, Djordjevic M. Probiotic function of the fermented milk Jogurt Plus. Paper presented at: FEMS Conference (Fifthe Symposium on Lactic Acid Bacteria), 1996; Holland. September 8-12.</citation>
  </reference>
  <reference>
    <citation>Nord CE, Lidbeck A, Orrhage K, Sjöstedt S. Oral supplementation with lactic acid-producing bacteria during intake of clindamycin. Clin Microbiol Infect. 1997 Feb;3(1):124-132.</citation>
    <PMID>11864087</PMID>
  </reference>
  <reference>
    <citation>Salminen S, Laine M, von Wright A, Vuopio-Varkila J, Kohonen T, Mattila-Sandholm T. Development of selection criteria for probiotic strains to assess their potential in functional foods: A Nordic and European approach. Bioscience Microflora. 1996;15(2):61-67.</citation>
  </reference>
  <reference>
    <citation>Black FT, Laulund S. A study on the recovery of ingested, encapsulated Lactobacillus acidophilus and Bifidobacteria bifidum from doudenal fluid and faeces. Chr. Hansen Internal Report. 1988.</citation>
  </reference>
  <reference>
    <citation>Abi-Hanna A, Moore N, Yolken RH, Saavedra JM. Long term consumption of infant formulas with live probiotic bacteria: safety and tolerance. Journal of Pediatric Gastroenterology and Nutrition. 1998;27(4):484.</citation>
  </reference>
  <reference>
    <citation>Saavedra JM, Abi-Hanna A, Moore N, Yolken RH. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr. 2004 Feb;79(2):261-7.</citation>
    <PMID>14749232</PMID>
  </reference>
  <reference>
    <citation>Lourens-Hattingh A, Viljoen BC. Yogurt as probiotic carrier food. International Dairy Journal. 2001;11(1-2):1-17.</citation>
  </reference>
  <reference>
    <citation>Tammam JD, Williams AG, Banks J, Cowie G, Lloyd D. Membrane inlet mass spectrometric measurement of O2 and CO2 gradients in cultures of Lactobacillus paracasei and a developing Cheddar cheese ecosystem. Int J Food Microbiol. 2001 Apr 11;65(1-2):11-22.</citation>
    <PMID>11322693</PMID>
  </reference>
  <reference>
    <citation>Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA. 1997 Sep 17;278(11):901-4.</citation>
    <PMID>9302241</PMID>
  </reference>
  <reference>
    <citation>Gill JM, Fleischut P, Haas S, Pellini B, Crawford A, Nash DB. Use of antibiotics for adult upper respiratory infections in outpatient settings: a national ambulatory network study. Fam Med. 2006 May;38(5):349-54.</citation>
    <PMID>16673197</PMID>
  </reference>
  <reference>
    <citation>Steinman MA, Gonzales R, Linder JA, Landefeld CS. Changing use of antibiotics in community-based outpatient practice, 1991-1999. Ann Intern Med. 2003 Apr 1;138(7):525-33.</citation>
    <PMID>12667022</PMID>
  </reference>
  <reference>
    <citation>Glass RI, Lew JF, Gangarosa RE, LeBaron CW, Ho MS. Estimates of morbidity and mortality rates for diarrheal diseases in American children. J Pediatr. 1991 Apr;118(4 Pt 2):S27-33.</citation>
    <PMID>2007954</PMID>
  </reference>
  <reference>
    <citation>Gangarosa RE, Glass RI, Lew JF, Boring JR. Hospitalizations involving gastroenteritis in the United States, 1985: the special burden of the disease among the elderly. Am J Epidemiol. 1992 Feb 1;135(3):281-90.</citation>
    <PMID>1546704</PMID>
  </reference>
  <reference>
    <citation>Ho MS, Glass RI, Pinsky PF, Young-Okoh NC, Sappenfield WM, Buehler JW, Gunter N, Anderson LJ. Diarrheal deaths in American children. Are they preventable? JAMA. 1988 Dec 9;260(22):3281-5.</citation>
    <PMID>3184416</PMID>
  </reference>
  <reference>
    <citation>Ho MS, Glass RI, Pinsky PF, Anderson LJ. Rotavirus as a cause of diarrheal morbidity and mortality in the United States. J Infect Dis. 1988 Nov;158(5):1112-6.</citation>
    <PMID>3183422</PMID>
  </reference>
  <reference>
    <citation>Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions to enhance medication adherence. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD000011. Review. Update in: Cochrane Database Syst Rev. 2008;(2):CD000011.</citation>
    <PMID>16235271</PMID>
  </reference>
  <reference>
    <citation>Winnick S, Lucas DO, Hartman AL, Toll D. How do you improve compliance? Pediatrics. 2005 Jun;115(6):e718-24. Review.</citation>
    <PMID>15930200</PMID>
  </reference>
  <reference>
    <citation>Ansah EK, Gyapong JO, Agyepong IA, Evans DB. Improving adherence to malaria treatment for children: the use of pre-packed chloroquine tablets vs. chloroquine syrup. Trop Med Int Health. 2001 Jul;6(7):496-504.</citation>
    <PMID>11469941</PMID>
  </reference>
  <reference>
    <citation>Nevins TE.</citation>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <last_update_submitted>May 17, 2013</last_update_submitted>
  <last_update_submitted_qc>May 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Daniel Merenstein</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>BB-12</keyword>
  <keyword>Yogurt</keyword>
  <keyword>Antibiotics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

